Please provide your email address to receive an email when new articles are posted on . Following the recent approvals of nintedanib and tocilizumab for systemic sclerosis-related interstitial lung ...
Hosted on MSN
Living better with scleroderma lung disease
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a serious complication affecting up to half of people with scleroderma, and it’s a leading cause of death. New guidelines and ...
Please provide your email address to receive an email when new articles are posted on . Patient-reported symptoms are associated with clinically impactful changes in systemic sclerosis disease ...
Age, specific disease-related elements, and treatment with glucocorticoids independently affect the risk for osteoporosis among patients with systemic sclerosis. Age, specific disease-related elements ...
Changes in Krebs von den Lungen 6 (KL-6) levels after 12 months of treatment with mycophenolate mofetil (MMF) or cyclophosphamide (CYC) are associated with the development of progressive pulmonary ...
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 ...
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally ...
Suggested Citation: "4 Scleroderma." National Academies of Sciences, Engineering, and Medicine. 2022. Selected Immune Disorders and Disability. Washington, DC: The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results